PPI Supplementation to Fight ECtopIc Calcification in PXE (PROPHECI-PPI)

Efficacy of PyROphosPHate Supplementation to Fight ECtopIc Calcification in PseudoXanthoma Elasticum - PROPHECI-PPI Study

Pseudoxanthoma elasticum (PXE) is a rare inherited metabolic disorder (OMIM 264800, frequency 1/25000) characterized by progressive ectopic calcification of connective tissues. PXE mainly affects the skin (inesthetic papules and plaques in the skin folds), the retina (central blindness), the vasculature (peripheral arterial occlusive disease and stroke) and the renal system (renal lithiasis) in adulthood. Although rarely, early lethal forms have been reported. This chronic and highly disabling condition results from a loss of function of the gene encoding for the ABCC6 membrane transporter primarily expressed in the hepatocytes and renal tubular cells. Recently, it has been reported that PXE was characterized by a 50-60% decrease in the plasma level of inorganic pyrophosphate (PPi), a major physiological anti-calcifying factor. PXE is an incurable disease which therapeutic options are limited to symptomatic treatments to stem the devastating effect of the ectopic calcifications. Recently, encouraging proof of concept studies with animals PXE models and healthy volunteers have shown that, contrary to what was initially reported and thought, the oral administration of PPi salts are able to increase PPi plasma levels, opening up new therapeutic perspectives in PXE. Therefore, we propose to perform the first Phase II randomized controlled trial (RCT) to evaluate the safety and efficacy of a daily and oral administration of PPi salts against placebo in PXE patients.

Study Overview

• Status: Recruiting
• Conditions: Pseudoxanthoma Elasticum
• Intervention / Treatment: Dietary supplement: study treatment PPI; Dietary supplement: Placebo comparator

• Study Type: Interventional
• Enrollment (Anticipated): 99
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Georges LEFTHERIOTIS, PUPH; Phone Number: 33 4 92 03 29 41; Email: leftheriotis.g@chu-nice.fr
• Study Contact Backup: Name: Sophie Bonnet; Email: bonnet.s@chu-nice.fr

Study Locations

• France
  • Angers, France, 49000
    • Recruiting
    • Angers Hospital
    • Contact: ludovic Martin, PHD; Phone Number: 33 2 41 35 34 19; Email: LuMartin@chu-angers.fr
    • Principal Investigator: ludovic Martin
    • Sub-Investigator: Emmanuel Letavernier
    • Sub-Investigator: Samir Henni
  • Nice, France, 06000
    • Recruiting
    • Nice hospital
    • Contact: Georges leftheriotis; Phone Number: 04 92 03 29 41; Email: leftheriotis.g@chu-nice.Fr
    • Principal Investigator: georges Leftheriotis

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 16 years to 63 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Patients (>18 years and <65 years), men and women, presenting a clinically and biologically authenticated PXE (genotype + phenotype) according to the international diagnostic criteria (26).
• Efficient contraceptive method in woman of childbearing age at inclusion and during the overall study
• Patient affiliated to a social security insurance
• Signed informed consent
• Patient without acute complication linked or not to the pathology at the time of the study

NON-INCLUSION CRITERIA

• Renal insufficiency (i.e. defined by a renal clearance <30ml / min / 1.73 m²)
• Patients with osteomalacia
• Patients with chronic diarrhea (> 1 month)
• Pregnancy, lactating or fertile women who may wish to become pregnant within three years.
• Any other medical condition that may be considered in the opinion of the Principal Investigator.
• Use of bisphosphonate during last 5 years.
• Hypocalcemia (calcium <2.20 mmol/L and ionized calcium <1.15 mmol/L) *.
• Vitamin D deficiency <35 nmol/L *
• Enrollment in another inteventional clinical trial which could interfere with the present study

• patients (>18 years) protected by law

  • After correcting the hypocalcemia and/or vitamin D deficiency, a participant is again suitable for participation in the trial, as long as the participant meets the inclusion criteria.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: PPI; the patient take PPI caps	Dietary supplement: study treatment PPI; patient take PPI every day during 12 months
Placebo Comparator: PPI placebo; The patient take PPI placebo	Dietary supplement: Placebo comparator; patient take PPI placebo every day during 12 months

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Arterial calcification score	Using manufacturer dedicated software, the investigator, will determine the calcification score from CT images according to the validated Agatston score method. A threshold of 130 Hounsfield Units for calcium detection will be used for the study. Voxels above this threshold representing arterial wall calcifications will be manually identified and selected by the observer on the CT image. Calcifications mass in the studied arterial segments will be analyzed and quantified. The length and antero-posterior mean diameter of each arterial segment will be determined for further normalization of the calcification score to the arterial wall surface (data expressed as HU/mm2 of arterial surface). The intraclass correlation and Bland-Altman coefficient for inter-observer reliability of the total peripheral artery calcium mass measurement will be determined by scoring 10 random scans by two independent investigators.	12 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
clinical observation of dermatological changes	number of patient with dematological changes. Dermatological changes will be monitored by a dermatoscopic study of the skin according to the following protocol: Images will be acquired from commonly affected areas (neck, axilla, antecubital fossae, armpits and periumbilical area) by a contact dermatoscope (SD) with non-polarized light and recorded, as previously described . The investigators will ensure that the very same areas are imaged at baseline and at the end of the study. The surface of SD elementary changes featuring yellow papulae (presenting as "dots" or "reticular networks") on digitized images will be compared using an open image processing software (ImageJ, https://imagej.nih.gov/ij/index.html NIH).	12 months
clinical observation of ophtalmologic changes	Number of patietns with ophtalmologic changes. These changes will be monitored (blinded to treatment) by the occurrence of subretinal neovascularization events, the frequency of anti-VEGF administration and the best-corrected visual acuity (BCVA). A sub-retinal neovascularization event will be defined as any of the following that provide an indication to start or intensify anti-VEGF injections to prevent (further) visual impairment: 1) retinal bleeding suspected to be caused by sub-retinal neovascularization (if needed confirmed by fluorescein angiography); 2) a significant increase in sub retinal or intraretinal fluid; and/or 3) growth of a sub retinal neovascular complex. These events will be scored by the trained ophthalmologist of the PXE reference center (Dr Th Bresson) who will be blinded for the treatment.	12 Montths
vascular changes	Ankle Brachial Index (ABI) at rest: Systolic arterial blood pressure will be recorded using a pneumatic cuff wrapped around the ankle. An ultrasound probe allows recording the blood flow in the left and right ankle arteries (namely posterior and anterior tibial arteries) and brachial arteries supine at rest. The ABI is determined by the ratio between the lowest ankle artery pressure and the highest brachial artery blood pressure. A peripheral arterial occlusive disease (PAOD) is defined according to the actual recommendations: an ABI <0.90) and an incompressible arterial wall reflecting mediacalcosis defined by ABI>1.40.	12 months

Collaborators and Investigators

• Sponsor: Centre Hospitalier Universitaire de Nice

Study record dates

Study Major Dates

• Study Start (Actual): December 13, 2022
• Primary Completion (Anticipated): December 13, 2023
• Study Completion (Anticipated): September 1, 2025

Study Registration Dates

• First Submitted: March 30, 2021
• First Submitted That Met QC Criteria: April 27, 2021
• First Posted (Actual): May 3, 2021

Study Record Updates

• Last Update Posted (Actual): December 19, 2022
• Last Update Submitted That Met QC Criteria: December 15, 2022
• Last Verified: December 1, 2022

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Cardiovascular Diseases; Vascular Diseases; Skin Diseases; Congenital Abnormalities; Hematologic Diseases; Hemorrhagic Disorders; Genetic Diseases, Inborn; Connective Tissue Diseases; Hemostatic Disorders; Skin Diseases, Genetic; Skin Abnormalities; Pseudoxanthoma Elasticum
• Other Study ID Numbers: 19-APN-01

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No